abrdn Life Sciences Investors
HQL
Get informed when a big investor buys or sells
+ FollowMarket Cap$551.91M
Close$
$-0.60
103.5% downside
Current Fair Value
103.5% downsideOvervalued by 103.5% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $551.91 Million |
|---|---|
| Enterprise Value | $551.91 Million |
| Dividend Yield | $2.24 (12.34%) |
| Earnings per Share | $2.96 |
| Beta | 0.73 |
| Outstanding Shares | 30,408,046 |
Return
| Return on Equity | 33.16% |
|---|---|
| Return on Assets | 33.02% |
| Return on Invested Capital | 26.57% |
Valuation & Multiples
| P/E Ratio | 2.69 |
|---|---|
| PEG | -1.13 |
| Price to Sales | 4.31 |
| Price to Book Ratio | 0.96 |
| Enterprise Value to Revenue | 4.05 |
| Enterprise Value to EBIT | 3.69 |
| Enterprise Value to Net Income | 2 |
| Total Debt to Enterprise | 0 |
| Debt to Equity | 0 |
Revenue Sources
No data
Insider Trades
Institutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.00000% |
|---|---|
| Total Calls | - |
| Total Puts | - |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 25.91%▼ 1.37% |
|---|---|
| Total Invested | $156.70M▲ 16.06% |
| Investors Holding | 86▼ 1.00% |
ESG Score
No data
About Tekla Life Sciences Investors
Tekla Life Sciences Investors is a closed-end fund that invests in public and private companies in the life sciences industry. Tekla Capital Management LLC, based in Boston, serves as Investment Adviser to the Fund.